NCT06823427

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE2

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Condition: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal | long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: rare_population_signal

Stopped reason

Context when available

No stop reason available in the current public record.